Prior to joining Eris, Ranganathan was Commercial Director, Women's Health, Metabolics, and International Business at Abbott India Limited
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Both organisations enter into a long- term collaboration to expand patient access in India
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
_256_384.jpg)
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
Biocon has reported consolidated financial results for the period ended December 31, 2021
Subscribe To Our Newsletter & Stay Updated
